Conflicts of interest in vaccine advisory committees: what the 2000 Congressional investigation found about FDA and CDC decision-makers who approved vaccines while holding financial ties to manufacturers.
A Congressional investigation report titled "Conflicts of Interest in Vaccine Policy Making", published June 15, 2000, examining the financial ties between members of FDA's vaccine committee (VRBPAC) and CDC's vaccine committee (ACIP) and the pharmaceutical industry. The report found systematic and pervasive conflicts of interest and issued damning conclusions about the integrity of both committees.
Background
The report was issued in the context of a period (roughly 1991–2000) during which a large portion of the vaccines now on the CDC childhood vaccine schedule were voted on, licensed, and recommended by these two committees. The same period in which Kathryn Edwards (and others) were simultaneously conducting pharma-funded trials and sitting on these committees.
Key Findings
FDA's VRBPAC
> "The overwhelming majority of members, both voting members and consultants, have substantial ties to the pharmaceutical industry."
CDC's ACIP
Equally condemned with similar language.
General Conclusions
"Loose standards" — significant conflicts of interest are not treated as conflicts
"Significant conflicts of interest are not deemed to be conflicts" — the ethics standards allowed the very conflicts that compromised independence
Policy effectively encourages "a system where government officials make crucial decisions affecting American children without the advice and consent of the governed"
Limitations of the Investigation
Aaron Siri notes the Congressional report identified only a fraction of actual conflicts. The Kathryn Edwards example demonstrates this clearly:
What the report identified: Edwards' $255,023/year contract from Wyeth Lederle (1996–1998) for pneumococcal vaccine study
What the report missed: Edwards' far more extensive conflicts — funding from Aventis, SmithKline Beecham, Merck; consulting for multiple companies; lecture fees; speakers' bureau memberships
If the investigation caught only a fraction of the conflicts, Siri argues, its conclusions would have been even more damning had the full picture been known.
Context: Vaccines Added During This Period
The vaccines on the current CDC childhood schedule that were voted on during this conflicted period include:
Hep B (3 doses, first 6 months)
DTaP (3 doses, first 6 months)
Hib (3 doses, first 6 months)
IPV (3 doses, first 6 months)
Varivax (chickenpox, first year)
Hep A (first year)
All manufactured by the same companies providing financial patronage to committee members.
Significance
The report provides Congressional-level validation of Siri's Regulatory Capture argument. Even official government investigators, using limited investigative tools, found that the committees responsible for vaccine licensure and schedule recommendations were dominated by individuals with substantial pharma ties. The report was published in 2000 and — per Siri's argument — its findings have not led to structural reform.
What did the 2000 Congressional investigation find about vaccine advisory committees?
The House Committee on Government Reform found that "the overwhelming majority of members, both voting members and consultants, have substantial ties to the pharmaceutical industry" on both FDA's VRBPAC and CDC's ACIP. The report concluded there were "loose standards" and that "significant conflicts of interest are not deemed to be conflicts." These committees were responsible for licensing and recommending the vaccines now on the childhood schedule.
Which vaccines were approved during the period of documented conflicts?
Vaccines approved by these conflicted committees include hepatitis B (3 doses in first 6 months), DTaP (3 doses in first 6 months), Hib (3 doses in first 6 months), IPV (3 doses in first 6 months), Varivax/chickenpox (first year), and hepatitis A (first year). All were manufactured by the same companies providing financial patronage to committee members who voted on their approval and schedule placement.
Did the Congressional investigation find all the conflicts?
No. Aaron Siri argues the investigation identified only a fraction of actual conflicts. The Kathryn Edwards example demonstrates this: the report caught her $255,023/year Wyeth Lederle contract but missed her far more extensive conflicts — funding from Aventis, SmithKline Beecham, and Merck, plus consulting fees, lecture fees, and speakers' bureau memberships from multiple companies. If the full picture had been known, the conclusions would have been even more damning.
What happened after the 2000 Congressional report was published?
Despite Congressional-level validation of systemic conflicts of interest, the report's findings did not lead to structural reform. The same committee structures remain in place. Committee members continue to hold financial ties to pharmaceutical companies whose products they evaluate and vote on. The report serves as a primary source documenting the conflicts that existed during the period when most current childhood vaccines were added to the schedule.
What specific conflicts did committee members have with vaccine manufacturers?
Documented conflicts include royalties from vaccine sales, consulting fees, corporate board seats at vaccine manufacturers, research funding from companies whose products members evaluated, speakers' bureau payments, paid travel, and endowed university chairs funded by pharmaceutical donations. Stanley Plotkin consulted for Merck, Pfizer, Sanofi, and GSK for decades. Julie Gerberding left the CDC directorship and became Merck's President of Vaccines, cashing in over $22 million in Merck stock.
This is the plain-HTML rendering of reports/2000 Congressional Report on FDA-CDC Conflicts.md, served for search
engines, AI crawlers, and accessibility tools. The interactive 3D version
of this wiki lives at vaccine-safety.org.